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Abstract. The introduction of artemisinin-based combination therapy in sub-Saharan Africa has prompted calls for
increased use of parasitologic diagnosis for malaria. We evaluated the cost-effectiveness of rapid diagnostic tests (RDTs)
in comparison to microscopy in guiding treatment of non-severe febrile illness at varying levels of malaria endemicity
using data on test accuracy and costs collected as part of a Tanzanian trial. If prescribers complied with current
guidelines, microscopy would give rise to lower average costs per patient correctly treated than RDTs in areas of both
high and low transmission. RDT introduction would result in an additional 2.3% and 9.4% of patients correctly treated,
at an incremental cost of $25 and $7 in the low and high transmission settings, respectively. Cost-effectiveness would be
worse if prescribers do not comply with test results. The cost of this additional benefit may be higher than many countries
can afford without external assistance or lower RDT prices.
INTRODUCTION
In response to the growth of resistance to standard antima-
larials, artemisinin-based combination therapy (ACT) is be-
ing introduced as a first-line drug in much of sub-Saharan
Africa (SSA).1 Its cost and the increasing recognition that
presumptive treatment leads to considerable drug expendi-
ture on inappropriate treatment of patients free of para-
sitemia have led to increased interest in parasitologic diagno-
sis. WHO and Tanzanian national guidelines now both rec-
ommend testing before treatment of patients over the age of
5 years,2,3 and WHO guidelines extend this recommendation
to younger children in low transmission settings.
In smaller health facilities in Africa, the only currently re-
alistic method of parasitologic diagnosis is through the use of
rapid diagnostic tests (RDTs). In larger facilities, where mi-
croscopic diagnosis is used, the results are frequently unreli-
able. This has led the Tanzanian National Malaria Control
Program to consider the use of RDTs for all routine outpa-
tient malaria diagnosis and to reserve the use of microscopy
to cases where a measure of parasite species or density is
needed or where treatment has been recently taken.
RDTs are a promising tool to target antimalarial treatment
because they require minimal infrastructure and simple train-
ing. RDTs have been shown to have sensitivity and specifici-
ties of > 90% in field conditions, a level rarely sustained for
routine microscopy in resource-constrained African coun-
tries.4–6 Additionally, because RDTs are potentially able to
provide rapid results that are directly visible to both pre-
scriber and patient, they have potential operational advan-
tages over microscopy. However, the cost implications of
their deployment relative to microscopy have not been exten-
sively studied. These may be considerable, and if so, will be an
influential factor in decisions whether to deploy them in
health facilities where microscopy already exists.2,7
MATERIALS AND METHODS
In July 2005, a randomized controlled trial was conducted
in three public hospitals in northeast Tanzania serving areas
where the transmission of malaria has previously been char-
acterized as very low, low, and high (parasite prevalence in
children younger than 5 years of age of 2%, 5%, and 61%,
respectively).8 Patients (N  2,416) for whom the clinician
had requested a parasitologic test for malaria were random-
ized to diagnosis using routine microscopy or an RDT for the
detection of Pf Histidine Rich Protein 2 antigen (Paracheck-
Pf, Orchid Biomedical Systems, Goa, India). In both arms,
reference slides were taken and later double-read according
to research methods.9 Data on treatments given were recorded.
The aim of the trial was 2-fold: to assess the accuracy of
RDTs compared with routine microscopy, and to examine the
effect of test results on clinician behavior. This paper focuses
on the former, using trial data on the tests’ accuracy and cost,
combined with ACT costs, to analyze the cost-effectiveness of
the use of the two tests to guide treatment in an operational
setting, where test performance is judged against the gold
standard of a double-read research slide. The cost and effec-
tiveness data were applied to parasite prevalence rates ob-
served in the high and low transmission settings to compare
the relative efficiency of each diagnostic approach in the two
settings. The results of the low and medium-low transmission
settings were combined in the analysis.
The analysis simulated scenarios where all patients, and
then only patients older than 5 years of age, were treated
according to parasitologic confirmation, representing the two
most common diagnostic algorithms recommended in ma-
laria-endemic countries. The main implications of including
the youngest age group are that younger patients require
smaller dosages, therefore incurring lower direct treatment
costs, and that parasite prevalence among young children is
higher, particularly in high transmission settings.
Test sensitivity and specificity were determined by compar-
ing pooled data on routine microscopy and on RDT results
from all three trial sites to reference slide results.
Costs were obtained from data collected in the low and
high prevalence settings, supplemented where necessary by
data from the literature. The costing perspective was that of
the provider. Costs were collected in Tanzanian Shillings of
2005 and converted to US dollars ($1  1,167 Tzs for 2005).
Slide costing combined micro-costing (noting all resources
used at the point of delivery and using an ingredients ap-
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proach to calculate their total economic cost) with step-down
costing of hospital expenditure to estimate indirect laboratory
costs. These costs were apportioned to the various laboratory
tests according to their proportional activity. Data for step-
down costing were obtained from hospital accounts and a
recent independent evaluation of all hospital assets.
The cost of RDTs was obtained directly from the manufac-
turer and included shipment costs plus 10% for local trans-
port and storage. The time needed for administration of the
tests was assumed to be equivalent to the preparation of a
blood slide.
The cost of ACT was estimated at $2.4 for an adult course
of artemether-lumefantrine, the current price negotiated be-
tween the World Health Organization and Novartis, the
manufacturer,2 and adjusted for patient age. These costs were
used in the analysis in place of costs of currently available
antimalarials to simulate the switch to artemether-lumefantrine
(Coartem, Novartis Pharma, Basel, Switzerland) in Tanzania as
the first-line drug for the treatment of uncomplicated malaria.
The cost of treatment of patients diagnosed as malaria
negative was estimated from data on the treatment cost of
trial patients who received an antibiotic but not an antima-
larial. The geometric mean was used for these because they
were highly skewed to the right.
The measure of effectiveness for this analysis was defined
as the proportion of patients correctly treated, in the context
of a strategy of parasitologic confirmation, assuming that pa-
tients with a positive test received an antimalarial, and pa-
tients that tested negative received an antibiotic. These two
measures were summed so that the provision of an antima-
larial to a true positive and the provision of alternative treat-
ment to true negatives were both included.
To evaluate the cost-effectiveness of the two diagnostic
strategies more broadly, the results were modeled across a
range of prevalence levels, assuming that all age groups were
tested and treated according to test results as defined above.
Two-way sensitivity analyses were carried out on malaria
prevalence and the cost of ACT, varying the latter to the
estimated cost of $1 for a cheaper combination and to a low-
est estimate for a scenario of high subsidies reducing their
cost to that of currently used antimalarials. Similarly, the cost
of the RDT was varied to assess the impact of a drop in price
(to an estimated minimum of 20 cents), which might result
from their larger-scale production.
In addition to an intervention’s cost-effectiveness, policy
makers need information on affordability. Thus, the total
costs were estimated for the management of 1,000 malaria-
suspected patients, using either microscopy or RDTs for di-
agnosis before treatment with ACT.
RESULTS
Microscopy costs. The cost per slide was $0.26. Labor was
the largest cost component, although staff took an average of
< 1.5 minutes before declaring a slide negative or providing a
positive result along with a parasitemia count.
Rapid diagnostic test costs. RDT costs were $0.81, the most
significant component being the test itself ($0.60).
Treatment costs. Geometric mean cost for treatment of pa-
tients diagnosed as not having a malarial illness was $0.42
compared with $2.40 for an adult course of Coartem.
Observed diagnostic accuracy and prevalence. Test speci-
ficity was comparably high for both tests—95% for RDT and
93% for microscopy—but RDTs were substantially more sen-
sitive (93%) than routine microscopy (71%) in this setting.
Data on test accuracy and prevalence were combined to
estimate the percentage of patients correctly treated. Table 1
summarizes the results for a strategy where all patients are
tested before treatment and also summarizes the results for
treating only patients older than 5 years of age by parasito-
logic confirmation. The difference in the proportion of pa-
tients correctly diagnosed by each method in areas of low
transmission is smaller, despite the lower sensitivity of slides,
a result of the lower likelihood of parasitemia.
Cost-effectiveness of RDTs and microscopy. Estimates of
cost-effectiveness per patient correctly treated were obtained
by summing diagnosis and treatment costs. These were di-
vided by the proportion of patients correctly treated to de-
termine the average cost per patient correctly treated. Incre-
mental costs were extrapolated from this in the standard man-
ner.10 The incremental cost represents the cost per additional
patient correctly treated by switching to the use of RDTs.
Low transmission setting. Under observed levels of slide
accuracy, if provision of ACT was reliant on a positive blood
slide and all patients were tested before treatment, the per-
centage of patients correctly treated would be 92.7%, at an
average cost per patient of $0.7. Replacing microscopy by
RDTs would raise the percentage of patients correctly treated
to 95%, at an average cost of $1.3 per patient correctly
treated. The incremental cost for each additional patient
treated correctly would be $25.2 in comparison to the use of
microscopy. If only patients older than 5 years of age were
tested before treatment, the results would vary only slightly
because of the small difference in prevalence by age group.
High transmission setting. In the high transmission setting,
prevalence rates were considerably higher, which in conjunc-
tion with the lower sensitivity obtained with microscopy
would result in 88.6% of patients being correctly treated at an
average cost of $1.1. With the use of RDTs, the percentage of
TABLE 1
Diagnostic accuracy of microscopy and RDTs according to the reference slide results in two transmission settings
Transmission
All patients are tested Only patients  5 years of age are tested
Low (prev  1.3%) High (prev  38.1%) Low (prev  1.55%) High (prev  20.8%)
RDT Slide RDT Slide RDT Slide RDT Slide
Missed case of malaria 0.1% 0.4% 2.6% 11% 0.1% 0.4% 1.5% 6.1%
Wrongly diagnosed malaria 4.9% 6.9% 3.1% 4.3% 4.9% 6.9% 4% 5.5%
Correct diagnosis of malaria 1.2% 0.9% 35.4% 27% 1.4% 1.1% 19.5% 14.5%
Correct diagnosis of non-malaria 93.8% 91.8% 58.9% 57.7% 93.6% 91.6% 75% 73.5%
Patients correctly diagnosed 95% 92.7% 94.2% 84.6% 95% 92.7% 94.5% 88.4%
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patients correctly treated would be 94.2%, with an average
cost of $1.7. Because of the larger difference in effectiveness,
the incremental cost would drop to $7.0 for each additional
patient correctly treated. If parasitic confirmation was re-
quired only for patients older than 5 years of age, their lower
prevalence (21%) would result in a slightly higher incremen-
tal cost-effectiveness ratio (ICER) of $10.1.
Differences in patient costs. In the trial, both tests were
administered to patients free of charge. The only significant
difference between the use of RDTs and microscopy was in
terms of total duration of the visit. Time from exiting first to
exiting second consultations was found to be lower by ∼50
minutes among patients randomized to the RDT group.
Sensitivity analyses. Figure 1 plots the incremental cost-
effectiveness of RDTs compared with microscopy against a
range of prevalences, showing that they become increasingly
cost-effective as prevalence increased. Figure 1 also shows the
effect of different ACT costs on the ICER. These include a
lower ACT cost to simulate the introduction of a cheaper
drug (such as dihydroartemisinin-piperaquine at ∼1 USD per
adult dose) and a much lower ACT cost to simulate a subsidy
that would reduce the cost to the consumer to that of current
antimalarials. As Figure 1 indicates, this had little impact on
the incremental cost, which was almost identical for all three
ACT prices.
The ICER was highly sensitive to change in the price of
RDTs, particularly where prevalence was low. As Figure 2
shows, should the price drop < 29 cents, RDTs could become
cost saving. At high prevalence, the ICER was far less sensi-
tive, although always less than $10 per patient correctly
treated.
Affordability. The total budget needed to treat 1,000 ma-
laria-suspected patients of all ages (a similar age structure to
that documented in the trial) by parasitologic confirmation
was consistently lower for microscopy in both transmission
settings, ranging from $932 to $1,260, as opposed to $1,507 to
$1,633 for RDTs (Figure 3). The difference between the two
is explained both by the higher cost of RDTs and by their
higher sensitivity with consequent higher use of ACTs.
Replacement of microscopy by RDTs would thus increase
costs by 61% and 30% at low and high prevalences, respec-
tively.
DISCUSSION
On the assumption that the introduction of more expensive
antimalarials will stimulate the increased use of parasitologic
diagnosis, our analysis compared the use of RDTs to micros-
copy in health facilities where the latter is available. We as-
sume full compliance of clinicians with test results because the
FIGURE 1. ICER for RDTs compared with microscopy by prevalence, with different price levels for ACT.
FIGURE 2. The ICER in relation to prevalence and RDT cost.
FIGURE 3. Total costs for management of 1,000 patients with the
use of either RDTs or microscopy.
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efficient use of parasitologic diagnosis is contingent on com-
pliance, as shown recently by Zerovac and others11 in their
evaluation of the financial implications of compliance with
microscopy results before treatment with artemether-
lumefantrine for febrile patients in Kenya.
We showed that, in both high and low transmission settings,
the use of microscopy results in lower average costs per pa-
tient correctly treated than the use of RDTs. However, the
slide results in this study were both less sensitive and specific
than RDT results. The incremental cost for each additional
patient correctly treated because of the higher accuracy of
RDTs ranged from $7 to $26, depending on transmission in-
tensity. Variations in ACT prices had little effect on results,
but they were very sensitive to reductions in the RDT price,
especially in the low transmission setting.
A multitude of studies have been carried out on the accu-
racy of RDTs in comparison to microscopy, but only three
studies were identified that compared their cost-
effectiveness,12–16 and only one of these incorporated treat-
ment costs. This study was conducted in Southeast Asia, with
significantly different epidemiologic and economic circum-
stances.12 The study here goes beyond these studies. It evalu-
ates the efficiency of RDTs within hospital settings where
microscopy is readily available, and it incorporates ACT costs
in an SSA setting. In terms of the interventions’ effectiveness,
our study includes the benefit of focusing on diagnosis not just
for malaria patients but also for those found to be parasite
negative.
In settings where microscopy is not a feasible option, the
cost-effectiveness of RDTs needs to be compared with that of
clinical diagnosis and presumptive treatment, the results of
which may differ substantially from our findings. Although
this was not the topic of our analysis, this will be a relevant
issue in many SSA locations.
Although data were drawn from a specific setting in Tan-
zania, there is no reason to believe that this setting is atypical.
The unit cost of blood slides, at $0.26, was comparable to
those calculated in previous studies, which ranged from $0.1
to $0.58.11,14,17,18 Results from studies that have evaluated the
accuracy of microscopy were either comparable to those
found in the trial12,19 or were somewhat worse.11,20 Where the
latter is the case, RDTs will seem somewhat more cost-
effective than findings here suggest.
The study has several limitations. With respect to costs,
only provider treatment and diagnosis costs were included
and not those for readmission of patients wrongly diagnosed/
treated or indirect costs such as productivity losses. Had these
been included, the cost-effectiveness of both tests, and of
RDTs in particular, is likely to have been greater. Patients
diagnosed with an RDT had a shorter wait, which if allowed
for would slightly reduce the additional cost of RDTs com-
pared with microscopy. Any inherent value to providers and
patients of speedier diagnosis was not allowed for.
Slide costs were treated as fixed, although in practice, they
will vary considerably with respect to volume. Because the
costs for maintaining microscopy facilities and technicians re-
mains fixed, lowering the output increases the average unit
cost.14,17 This implies that, in peripheral dispensaries where
the volume is lower than that observed in the trial hospitals,
RDTs will be increasingly cost-effective.
“Patients correctly treated” was defined as provision of an-
timalarials to test positives; for patients who were test nega-
tive, there was no such convenient definition of correct treat-
ment without further information on the exact nature of other
febrile illnesses. In the absence of better data, it was assumed
that the treatment cost of test negatives was represented by
that of trial patients who received an antibiotic and not an
antimalarial. In reality, a more diverse range of treatments
may be given to test negatives.
The huge burden of malaria in Africa means that even
small differences in the cost of treatment or diagnosis can
have large economic effects. In the public sector in Tanzania
in 2004, > 11 million treatments for malaria were prescribed;
the extent of slide testing in these patients is not routinely
reported, but several studies have now documented that a
high proportion of treatments for malaria are in patients who
are either not tested or who have been tested but have a
negative result.
The much higher drug costs that are resulting from the
deployment of ACT is stimulating debate on the role of para-
sitologic diagnosis. We showed that the choice between RDTs
and microscopy is not straightforward, because RDTs were
found to be not just more accurate but also more costly. In the
context of SSA health budgets, the additional cost of up to
$26 for the benefit of correctly treating a patient is not insig-
nificant, suggesting that both external assistance for increas-
ing the volume of diagnosis and finding ways of reducing the
cost of RDTs are important. Moreover, regardless of which
diagnostic test is used, attention must be focused on encour-
aging clinician compliance with test results, because the lower
this is, the worse the cost-effectiveness of diagnosis and treat-
ment will be.
Cost-effectiveness studies such as this should ideally in-
clude extrapolation to final health outcomes. This is espe-
cially important to capture adequately the benefits of testing
for patients with non-malaria febrile illnesses. Lack of infor-
mation on such illnesses led us to evaluate the diagnostic tests
in terms of patients correctly treated. Improving the evidence
base to permit a complete cost-effectiveness analysis is a re-
search priority.
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